BioGaia AB Class B

As of June 30, 2026, BioGaia AB Class B carries a market capitalization of 11.83B, placing it among publicly traded companies globally. Its enterprise value stands at 11.38B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioGaia AB Class B's next confirmed earnings release is scheduled for February 12, 2027.

As of June 30, 2026, BioGaia AB Class B has 101.16M shares outstanding.

As of June 30, 2026, BioGaia AB Class B trades at a trailing price-to-earnings ratio of 32.03. The price-to-sales ratio is 7.13, and the price-to-book ratio stands at 10.74.

As of June 30, 2026, BioGaia AB Class B trades at an EV/EBITDA multiple of 23.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 24.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. BioGaia AB Class B trades at an EV/FCF ratio of 42.10, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 11.38B versus a market cap of 11.83B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioGaia AB Class B maintains a current ratio of 4.44, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, BioGaia AB Class B posted a return on equity (ROE) of 25.64, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 25.26 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.92, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 25.90, useful for judging operating efficiency across full business cycles. The company generates approximately 6.98M in revenue per employee across its workforce of 237.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, BioGaia AB Class B recorded 100.27M in income tax expense. That works out to an effective tax rate of 21.36, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 469.52M, leaving 369.25M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, BioGaia AB Class B's stock has gained approximately 22.56% over the past 52 weeks. The 50-day moving average sits at 114.82, while the 200-day moving average is 116.20.

Over the twelve months ended June 30, 2026, BioGaia AB Class B generated 1.66B in revenue and converted that into 369.25M in net income, yielding earnings per share of 3.65. EBITDA reached 487.09M, while operating income came in at 462.59M.

These figures are as of June 30, 2026. Total book value stands at 1.10B, with working capital of 728.98M providing operational flexibility.

BioGaia AB Class B produced 281.82M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -15.27M in capital expenditures, free cash flow totaled 266.55M - equivalent to 2.63 per share.

Over the twelve months ended June 30, 2026, BioGaia AB Class B posted a gross margin of 72.67, reflecting its pricing power and cost economics. The operating margin of 27.89 and net profit margin of 22.26 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, BioGaia AB Class B paid dividends of 10.90 per share. The dividend payout ratio of 298.62 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.25, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BioGaia AB Class B shareholders.

BioGaia AB Class B's most recent stock split took place on May 18, 2022 with a 1:5 split ratio.